VTP-500 / Barinthus Bio, CEPI, University of Oxford - LARVOL DELTA

Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure (ESCMID Global 2025) - No abstract available

Clinical • Late-breaking abstract • Respiratory Diseases

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. (PubMed, Int Immunopharmacol) - "The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines."

Journal • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels. (PubMed, Vaccines (Basel)) - "MVA-MERS vaccine, administered in a homologous prime-boost regimen, induced high levels of neutralising anti-MERS-CoV antibodies in mice and camels. This could be considered for further development and evaluation as a dromedary vaccine to reduce MERS-CoV transmission to humans."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. (PubMed, Lancet Microbe) - P1 | "ChAdOx1-vectored vaccine candidates against several pathogens have been developed and tested in clinical trials and ChAdOx1 nCoV-19 has now been licensed for emergency use for COVID-19. The acceptable safety and immunogenicity data from this phase 1b trial of ChAdOx1 MERS vaccine candidate in Healthy Middle Eastern adults, combined with previous safety and immunogenicity data from a trial in the UK, support selecting the ChAdOx1 MERS vaccine for advancement into phase 2 clinical evaluation. UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research; and King Abdullah International Medical Research Center."

Clinical • Journal • P1 data • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Orthopedics • Pain

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001) (clinicaltrials.gov) - P1; N=29; Terminated; Sponsor: University of Oxford; N=48 ➔ 29; Trial completion date: Sep 2022 ➔ Sep 2021; Suspended ➔ Terminated; Trial primary completion date: Sep 2022 ➔ Sep 2021; The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Transcriptomic Profiling of Dromedary Camels Immunised with a MERS Vaccine Candidate. (PubMed, Vet Sci) - "The camel Bcl-3 and Bcl-6 transcripts were significantly upregulated, indicating a strong activation of Tfh cell, B cell, and NF-κB pathways. In conclusion, this study gives an overall view of the first changes in the immune transcriptome of dromedaries after vaccination; it supports the potency of ChAdOx1 MERS as a potential camel vaccine to block transmission and prevent new human cases and outbreaks."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • BCL3 • BCL6

Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. (PubMed, NPJ Vaccines) - "mCuMV-MERS vaccine is self-adjuvanted with ssRNA, a TLR7/8 ligand which is spontaneously packaged during the bacterial expression process. The developed vaccine candidate induced high anti-RBD and anti-spike antibodies in a murine model, showing high binding avidity and an ability to completely neutralize MERS-CoV/EMC/2012 isolate, demonstrating the protective potential of the vaccine candidate for dromedaries and humans."

Journal • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Tetanus

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001) (clinicaltrials.gov) - P1; N=48; Suspended; Sponsor: University of Oxford; Trial completion date: Jul 2021 ➔ Sep 2022; Recruiting ➔ Suspended; Trial primary completion date: Jul 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002) (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: King Abdullah International Medical Research Center; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. (PubMed, Sci Adv) - "Transgenic human dipeptidyl peptidase 4 mice vaccinated with ChAdOx1 MERS were completely protected against disease and lethality for all different MERS-CoV strains. The data support further clinical development of ChAdOx1 MERS."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. (PubMed, Lancet Infect Dis) - P1 | "ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials."

Clinical • Journal • P1 data • Hepatitis B • Hepatitis C Virus • Hepatology • Infectious Disease • Novel Coronavirus Disease